RNA Editing Partnerships ProQR's proprietary Axiomer ADAR mediated RNA editing platform offers a licensing or co development opportunity for pharma and biotech partners seeking to add editing capabilities to their therapeutic programs. The platform's versatility suggests potential across diverse indications, enabling collaborations without building editing capabilities in house. Business development should consider licensing models with upfront payments and milestone based structures, plus options for collaborative research and development support.

Rett Therapy Focus ProQR has secured funding for Rett syndrome research and publicly positions RNA editing as a route to address unmet neurological needs. This creates targeted sales opportunities with academic labs, patient advocacy groups, biotech consortia, and potential licensing deals centered on Rett programs or platform enabled approaches to neurological diseases.

Regional Expansion Leiden headquarters combined with active engagement in North American events indicates readiness for cross border collaborations. The dual market footprint and conference activity point to opportunities to pursue EU and US co development deals, research collaborations, and strategic partnerships with mid to large biotech companies.

Investor Outreach Active participation in Citizens Life Sciences Conference, Evercore Healthcare Conference, and the annual general meeting discussions signals ongoing investor outreach and potential strategic funding conversations. BD teams could align with investors interested in platform licensing, milestone financing, or collaborative programs to accelerate preclinical and clinical work.

Governance Signals Board changes planned for the upcoming annual general meeting suggest potential shifts in strategic priorities and partnership focus. BD teams should monitor leadership announcements for signals about preferred collaboration models, indications of funding needs, or new partnerships.